Eris Lifesciences Ltd
ERISEris Lifesciences Ltd
ERIS
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.84 | 6.36 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast from 9 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 600.39 | 774.61 | 882.01 | 1,013.85 | 1,089.46 | 1,220.57 | 1,373.13 | 1,743.83 | 2,080.10 | 2,523.65 | ||||||||||
Raw Materials | 89.94 | 107.73 | 136.92 | 167.12 | 150.12 | 276.44 | 259.29 | 348.53 | 379.32 | 1,659.68 | ||||||||||
| Power & Fuel Cost | 3.59 | 3.02 | 3.17 | 3.45 | 4.62 | 3.95 | 4.16 | 5.70 | 12.04 | |||||||||||
| Employee Cost | 124.67 | 131.22 | 157.32 | 190.66 | 205.69 | 229.30 | 250.18 | 346.16 | 403.82 | |||||||||||
| Selling & Administrative Expenses | 189.79 | 204.42 | 224.28 | 279.66 | 238.82 | 210.94 | 256.10 | 375.66 | 426.75 | |||||||||||
| Operating & Other expenses | 17.33 | 33.97 | 11.81 | -3.80 | 106.30 | 60.49 | 92.28 | 119.88 | 159.52 | |||||||||||
EBITDA | 175.07 | 294.25 | 348.51 | 376.76 | 383.91 | 439.45 | 511.12 | 547.90 | 698.65 | 863.97 | ||||||||||
| Depreciation/Amortization | 20.36 | 22.76 | 25.64 | 36.35 | 50.26 | 42.99 | 64.71 | 117.09 | 182.61 | 256.04 | ||||||||||
| PBIT | 154.71 | 271.49 | 322.87 | 340.41 | 333.65 | 396.46 | 446.41 | 430.81 | 516.04 | 607.93 | ||||||||||
| Interest & Other Items | 0.28 | 1.10 | 10.65 | 23.06 | 2.30 | 1.98 | 4.22 | 26.17 | 84.80 | 170.99 | ||||||||||
| PBT | 154.43 | 270.39 | 312.22 | 317.35 | 331.35 | 394.48 | 442.19 | 404.64 | 431.24 | 436.94 | ||||||||||
| Taxes & Other Items | 20.88 | 23.60 | 18.12 | 26.56 | 34.86 | 39.36 | 36.08 | 22.48 | 39.26 | 88.48 | ||||||||||
| Net Income | 133.55 | 246.79 | 294.10 | 290.79 | 296.49 | 355.12 | 406.11 | 382.16 | 391.98 | 348.46 | ||||||||||
| EPS | 9.71 | 17.95 | 21.39 | 21.15 | 21.70 | 26.15 | 29.89 | 28.11 | 28.82 | 25.62 | ||||||||||
| DPS | 6.04 | 0.00 | 0.00 | 0.00 | 2.87 | 5.50 | 6.01 | 7.35 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.62 | 0.00 | 0.00 | 0.00 | 0.13 | 0.21 | 0.20 | 0.26 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Eris Lifesciences Ltd | 52.31 | 6.36 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare ERIS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 6.58%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.51%
Top 5 Mutual Funds holding Eris Lifesciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4741% | Percentage of the fund’s portfolio invested in the stock 0.56% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 58/221 (+4) |
Franklin India Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3892% | Percentage of the fund’s portfolio invested in the stock 1.74% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/72 (+1) |
UTI Small Cap Fund - Direct Growth Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3411% | Percentage of the fund’s portfolio invested in the stock 1.50% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/98 (-3) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Eris Lifesciences Ltd
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹7.35
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹6.01
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 13, 2020
Dividend/Share
₹5.50
Ex DateEx Date
Aug 13, 2020
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹2.87
Ex DateEx Date
Mar 19, 2020
The Board of Eris Lifesciences at its meeting held on 25 October 2024 has approved the execution of Binding Term Sheet with Levim Lifetech and its shareholders for the purpose of acquiring 30% stake in Levim Lifetech for an investment of Rs 54 crore at a pre-money equity valuation of Rs 126 crore. The acquisition is aimed at expansion of the company's biotechnology footprint across a wide range of products and technologies. Powered by Capital Market - Live
Net profit of ERIS Lifesciences declined 25.80% to Rs 91.59 crore in the quarter ended September 2024 as against Rs 123.43 crore during the previous quarter ended September 2023. Sales rose 47.64% to Rs 738.95 crore in the quarter ended September 2024 as against Rs 500.52 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales738.95500.52 48 OPM %35.8036.19 - PBDT209.59168.33 25 PBT129.11126.24 2 NP91.59123.43 -26 Powered by Capital Market - Live
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
ERIS Lifesciences announced that the 18th Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25
Eris Lifesciences Q1 Results: Net dips 4.5% YoY at Rs 89 crore
ERIS Lifesciences consolidated net profit declines 12.31% in the June 2024 quarter
Net profit of ERIS Lifesciences declined 12.31% to Rs 83.18 crore in the quarter ended June 2024 as against Rs 94.86 crore during the previous quarter ended June 2023. Sales rose 55.55% to Rs 715.59 crore in the quarter ended June 2024 as against Rs 460.03 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales715.59460.03 56 OPM %34.9336.90 - PBDT191.26153.38 25 PBT115.32112.49 3 NP83.1894.86 -12 Powered by Capital Market - Live
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live
2 top stock recommendations from Aditya Arora
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.46%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.46% to 0.55%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 6.15%, vs industry avg of 15.27%